HeartWare International Rating Reiterated by Canaccord Genuity (HTWR)
HeartWare International (NASDAQ:HTWR)‘s stock had its “buy” rating restated by investment analysts at Canaccord Genuity in a note issued to investors on Monday, AnalystRatingsNetwork reports. They currently have a $110.00 target price on the stock. Canaccord Genuity’s target price points to a potential upside of 57.17% from the stock’s previous close.
A number of other analysts have also recently weighed in on HTWR. Analysts at Oppenheimer cut their price target on shares of HeartWare International from $95.00 to $89.00 in a research note to investors on Monday. They now have a “market perform” rating on the stock. Separately, analysts at Raymond James cut their price target on shares of HeartWare International from $110.00 to $100.00 in a research note to investors on Monday, August 12th. Finally, analysts at Barclays Capital reiterated an “overweight” rating on shares of HeartWare International in a research note to investors on Friday, August 9th. They now have a $100.00 price target on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $93.17.
Shares of HeartWare International (NASDAQ:HTWR) opened at 69.99 on Monday. HeartWare International has a one year low of $69.53 and a one year high of $99.68. The stock has a 50-day moving average of $77.19 and a 200-day moving average of $87.72. The company’s market cap is $1.151 billion.
HeartWare International (NASDAQ:HTWR) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.73) by $0.06.
Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.